Dextromethorphan in nonketotic hyperglycinaemia: Metabolic variation confounds the dose-response relationship

Journal of Inherited Metabolic Disease

Volumn 20, Issue 1, 1997, Pages 28-38

  Arnold, G L ^a   Griebel, M L ^b   Valentine, J L ^b   Koroma, D M ^b   Kearns, G L ^c,d  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b ARKANSAS CHILDREN S HOSPITAL   (United States)

^c CHILDREN S MERCY HOSPITAL   (United States)

^d UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CYTOCHROME P450; DEXTROMETHORPHAN; DEXTRORPHAN; GLYCINE; GLYCINE CLEAVAGE SYSTEM;

CHILD; CLINICAL ARTICLE; DOSE RESPONSE; DRUG METABOLISM; FEMALE; HUMAN; HYPERGLYCINEMIA; INFANT; NEWBORN; REVIEW; SCHOOL CHILD;

CHILD; DEXTROMETHORPHAN; DEXTRORPHAN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA; INFANT, NEWBORN; N-METHYLASPARTATE; SEIZURES;

EID: 0031049313     PISSN: 01418955     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005301321635     Document Type: Review

References (26)

1. 450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 29: 192-209.
2. Dollery C (ed.) (1991) Dextromethorphan. In: Therapeutic Drugs, volume I. New York: Churchill Livingstone, D63 - D66.
3. Ferkany JW, Borosky SA, Clissold DB, Pontecorvo MJ (1988) Dextromethorphan inhibits NMDA-induced convulsions. Eur J Pharmacol 151: 151 - 154.
4. Greenshcr J, Mofenson HC, Caraccio T (1983) Bromide, In Haddad LM, Winchester JF, eds. Clinical Management of Poisoning and Drug Overdose. Philadelphia: WB Saunders, 685.
5. Hamosh A, McDonald JW, Valle D, Francomano CA, Niedermeyer E, Johnston MV (1992) Dextromethorphan and high close benzoate therapy for nonketotic hyperglycinemia in an infant. J Pediatr 121: 131 - 135.
6. Jacqz-Aigrain E, Funck-Brentano C, Cresteil T (1993) CYP2D6 and CYP3A dependent metabolism of dextromethorphan in humans. Pharmacogenetics 3: 197 - 204.
7. Kearns GL (1995) Pharmacogeneties and development: are infants and children at increased risk for adverse outcomes? Curr Opin Pediatr 7: 220 - 233.
8. Langan TJ, Pueschel S (1983) Nonketotic hyperglycinemia: clinical, biochemical and therapeutic considerations. Curr Probl Pediair 13: 1 - 29.
9. McDonald JW, Johnston MV (1990) Non-ketotic hyperglycinemia: pathophysiological rule of the N-methyl-D-aspartate type amino acid receptors. Ann Neurol 27: 449 - 450.
10. Murray M (1992) P450 enzymes: inhibition mechanisms, genetic regulation and effects of liver disease. Clin Pharmacokinet 23: 132 - 146.
11. Netzer R, Pflimlin P, Trube G (1991) Dextromethorphan blocks the NMDA-induced current- and voltage-gated calcium currents in cultured cortical neurons. Naunyn Schmiedebergs Arch Pharmacol 334 (supplement 22): 122 (abstract).
12. Nyhan WL (1989) Nonketotic hyperglycinemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D. eds. The Metabolic Basis of Inherited Disease, 6th edn. New York: McGraw-Hill, 743 - 753.
13. Ohyo Y, Ochi N, Mizutani N, Hayakawa C, Watanabe K (1991) Nonketotic hyperglycinemia and treatment with NMDA antagonist and consideration of neuropathogenesis. Pediatr Neurol 7: 65 - 68.
14. Prince DA, Feesor HR (1988) Dcxtromcthorphan protects against cerebral infarction in the rat model of hypoxia-ischcmia. Neurosci Lett 85: 291 - 296.
15. Rumack BH, Lovejoy FH Jr (1986) Clinical Toxicology. In Klassen CD, Amdur MO, Doull J, eds. Casarett and Doull's Toxicology, The Basic Science of Poisons. New York: Macmillan, 881.
16. Schmitt B, Steinmann B (1993) Dextromethorphan in infantile nonketotic hyperglycinemia. J Pediatr 122: 324 - 325.
17. Schmitt B, Steinmann B, Gitzelmann R, Thun-Hohensten L, Maschcr H, Dunermuth G (1993) Non-ketotic hyperglycinemia: clinical and electrophysiologic effects of dextromethorphan, an antagonist of the NMDA receptor. Neuro 43: 421 - 424.
18. Tada K (1987) Nonketotic hyperglycinemia: clinical and metabolic aspects. Enzyme 38: 27 - 35.
19. Tegtmeyer-Metzdorf H, Roth B, Gunther M, Theisohn M, Heinemann U, Adams HA, Sticht G (1995) Ketamine and strychnine treatment of an infant with nonketotic hyperglycinemia. Eur J Pediatr 154: 649 - 653.
20. Trijbels JMF, Monnens LAH, Vanderzee SPM, Vrenken JAT, Sengcrs RCA, Schrctlcn EDAM (1974) A patient wth nonketotic hyperglycinemia: biochemical findings and therapeutic approaches. Pediatr Res 8: 598 - 605.
21. von Wendt L, Simila S, Saukkonen AL, Kovisto M (1980) Failure of strychnine treatment during the neonatal period in three Finnish children with nonketotic hyperglycinemia. Pediatrics 65: 1199 - 1169.
22. Wolff JA, Kulovich S, Yu AL, Chong-Nian Q, Nyhan WL (1986) The effectiveness of benzoate in the management of seizures in nonketotic hyperglycinemia. Am J Dis Child 140: 596 - 602.
23. Wong BY, Coulter DA, Choi DW, Prince DA (1988) Dextrorphan and dextromethorphan, common antitussives, are antiepileptic and antagonize N-methyl-D-aspartate in brain slices. Neurosci Lett 85: 261 - 266.
24. Woodworth JR, Dennis SRK, Hinsvark OV, Amsel LP, Rotenberg KS (1987a) Bioavailability evaluation of a controlled-release of Dextromethorphan liquid. J Clin Pharmacol 27: 133-138.
25. Woodworth JR, Dennis SRK, Moore L, Rotenberg KS (1987b) The polymorphic metabolism of dextromethorphan. J Clin Pharmacol 27: 139 - 143.
26. Zhang Y, Britto MR, Valderhaugh KL, Wedlund PJ, Smith RA (1992) Dextromethorphan: enhancing its systemic availability by way of low-dose quinine-mediated inhibition of cytochrome P4502D6. Clin Pharmacol Ther 51: 647 - 655.